Combination Pharmaceutical Therapies for Obesity  Conclusions Data available at the time of writing this paper suggest that drug combinations in development discussed in this article have achieved significantly greater weight loss than individual components and far greater weight loss than placebo. Data from phase III trials of longer duration and involving several thousand subjects will give us critical information regarding safety and tolerability. In light of the safety issues that surfaced with the phen-fen combination in the past, demonstration of safety is paramount. 